Xcout IntelYarrow Bioscience
Yarrow Bioscience is a U.S.-based biotechnology company focused on the development of treatments for autoimmune diseases. The company has been involved in significant pharmaceutical deals, including the acquisition of drug candidates for thyroid conditions.
Subscribe to see Yarrow Bioscience’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Yarrow Bioscience at a glance
Yarrow Bioscience is a pharmaceutical company headquartered in New Haven, United States. It is publicly listed (YARW) with a market capitalisation of $602,204. Xcout tracks 24 named people at Yarrow Bioscience, including David T. Domzalski (Chief Executive Officer, President & Director).
Yarrow Bioscience leadership
- David T. DomzalskiChief Executive Officer, President & Director
- Rebecca Velez FreyChief Executive Officer, President & Director
- Rachael Alford, PhDChief Operating Officer
- Tyler ZerondaChief Financial Officer
- Iain A. StuartChief Scientific Officer
- Mutya HarschGeneral Counsel, Chief Legal Officer & Company Secretary
18 more named people on record for Yarrow Bioscience, with roles, board committees and tenure — see the full roster →
Recent Yarrow Bioscience news
2 corporate events on record, with sources — see the full timeline →
Yarrow Bioscience competitors
A few of Yarrow Bioscience's closest competitors — see the full list of competitors and alternatives →
Harrow is a Nashville, Tennessee-based pharmaceutical provider that entered into an agreement to acquire the Tyrvaya dry eye treatment from Viatris Inc.
Sparrow Pharmaceuticals, Inc. is a Boston-based biopharmaceutical company focused on developing targeted cardiometabolic therapeutics. The company aims to address conditions such as diabetes and endocrine diseases with precision therapies.
Bionyra Pharma is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for severe immunological and inflammatory conditions. The company launched with a $165 million oversubscribed Series A funding round.
Highlightll Pharma is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China. The firm focuses on the research and development of treatments for both peripheral and central autoimmune and inflammatory diseases.
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Newark, California, focused on developing therapies for liver and other chronic diseases before being acquired by Gilead Sciences.
NYB Holdings Ltd operates an AI-first drug discovery and biotechnology platform that utilizes a large natural compound library and predictive modeling to identify bioactive compounds. The company develops science-backed wellness solutions for nutraceutical applications and advances high-potential drug candidates into preclinical development for the pharmaceutical industry.
Get Yarrow Bioscience's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Yarrow Bioscience in Xcout Intel
- 24 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access